Related Experiment Videos
Danazol in Indian haemophiliacs
S Sundar1, G S Moorleedhur-Singh, B Dube
1Department of Medicine, Institute of Medical Sciences, Banaras Hindu University Varanasi, India.
The Journal of the Association of Physicians of India
|January 1, 1993
Summary
Danazol therapy increased factor-VIII levels in patients with haemophilia-A, particularly those with lower baseline levels. The therapeutic effect persisted post-treatment without observed adverse effects.
Area of Science:
- Hematology
- Pharmacology
Background:
- Haemophilia-A is a bleeding disorder caused by a deficiency in factor-VIII.
- Current treatments for haemophilia-A involve factor replacement therapy.
Purpose of the Study:
- To evaluate the efficacy of danazol in increasing factor-VIII levels in patients with haemophilia-A.
- To assess the duration of the effect and safety profile of danazol therapy.
Main Methods:
- A total of 30 patients with haemophilia-A received danazol at a dose of 10 mg/kg/day (max 600 mg/day) in two divided doses for 14 days.
- Factor-VIII levels were monitored at baseline, day 7, day 14, and two weeks after cessation of therapy.
Main Results:
- All patients showed an increase in factor-VIII levels after one week of danazol therapy.
- Patients with baseline factor-VIII levels below 1% experienced a 3-6 fold increase, with mean levels reaching 2.3% at day 7 and 4.8% at day 14.
- A marginal increase was observed in patients with baseline factor-VIII levels above 3%.
- Elevated factor-VIII levels persisted for two weeks after discontinuing danazol.
- No adverse effects were reported during or after the treatment period.
Conclusions:
- Danazol effectively increases factor-VIII levels in patients with haemophilia-A, especially in those with severe deficiency.
- The observed increase in factor-VIII levels is sustained post-treatment.
- Danazol appears to be a safe therapeutic option for managing haemophilia-A.